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Background: Mesenchymal stromal cells in the endosteal niche lining compact bone (CB-MSCs) represent a
heterogeneous population, all of which contribute to bone repair and remodelling. Hyperglycaemia associated with
type 2 diabetes mellitus (T2DM) can delay and impair the bone healing process. Therefore, this study investigated
the influences of high (25 mM) glucose conditions on CB-MSC populations isolated from male Wistar rats, versus
normal (5.5 mM) glucose conditions; in terms of proliferation (population doublings, PDs), senescence
characteristics, stem cell marker expression, colony forming efficiencies (CFEs); and osteogenic/adipogenic
differentiation, following extended culture in vitro.
Results: CB-MSCs under both normoglycaemic and hyperglycaemic conditions demonstrated similar morphologies
and rapid exponential growth to >300PDs, although high glucose conditions promoted more rapid and persistent
proliferation beyond ~50PDs, with few indications of senescence. Limited senescence was confirmed by minimal
SA-β-galactosidase staining, low senescence marker (p53, p21waf1, p16INK4a) expression and positive telomere
maintenance marker (rTERT, TR) expression. However, telomere lengths varied throughout culture expansion, with
hyperglycaemia significantly reducing telomere lengths at PD50 and PD200. Furthermore, CB-MSCs expanded in
normal and high glucose conditions remained non-transformed, exhibiting similar MSC (CD73/CD90/CD105),
multipotency (CD146) and embryonic (Slug, Snail) markers throughout extended culture, but negligible
hematopoietic (CD34/CD45) or pluripotency (Nanog, Oct4) markers. Hyperglycaemia significantly increased CFEs at
PD50 and PD100, which decreased at PD200. CB-MSC osteogenic differentiation was also inhibited by
hyperglycaemia at PD15, PD100 and PD200, but not at PD50. Hyperglycaemia inhibited CB-MSC adipogenic
differentiation to a lesser extent at PD15 and PD50, with reduced adipogenesis overall at PD100 and PD200.
Conclusion: This study demonstrates the limited negative impact of hyperglycaemia on the proliferative and stem
cell characteristics of heterogeneous CB-MSC populations, although minor sub-population(s) appear more
susceptible to these conditions leading to impaired osteogenic/adipogenic differentiation capabilities. Such findings
potentially highlight the impact of hyperglycaemia on CB-MSC bone repair capabilities in situ.
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Bone repair occurs via a multiple number of highly coor-
dinated and overlapping events, involving various cell
types, signalling molecules and extracellular matrix (ECM)
components to re-establish normal bone architecture and
function [1–4]. Such events are clinically important to
successful fracture repair, orthopaedic/dental implant
placement and bone augmentation outcomes. At the fore-
front of these reparative processes are the functions of
mesenchymal stromal cells (MSCs), attributed to their de-
fined self-renewal properties and abilities to undergo
growth factor-driven, differentiation along the osteogenic
lineage into mature osteoblasts; which drive ECM synthe-
sis, deposition and mineralisation [1–3].
The primary sources of MSCs during bone repair have
been suggested to exist within two principle, but distinct,
niches within the bone marrow cavity [5]. The highly
vascularised perivascular/sub-endosteal niche contains
endothelial cells, hematopoietic stem cells (HSCs) and
uncommitted MSCs [6–8]. In contrast, the endosteal
niche exists at the interface between trabecular bone and
bone marrow, organised around hematopoietic cells and
uncommitted MSCs interacting with pre-osteoblasts and
osteoblasts lining the compact bone [9, 10]. These more
committed, lineage restricted bone lining progenitor
cells have been proposed to represent the first responder
cells during mineralised tissue repair and remodelling,
with the immature MSCs subsequently proliferating to
replace the former cell population [11, 12]. Recent char-
acterisation studies on MSCs isolated from the endosteal
niche of compact bone (CB-MSCs) have identified the
ability to culture the pre-osteoblasts and osteoblasts
along with immature MSCs to 15 population doublings
(PD15), correlating with high osteogenic capabilities and
minimal evidence of cellular senescence [12]. More pro-
longed culture expansion resulted in the more highly
proliferative immature MSCs and transit amplifying
(TA) cells dominating the cell population, which is com-
mensurate with increased bi-potentiality for osteogenic
and adipogenic induction. Notably these cells were able
to continue to proliferate to beyond PD100 without
exhibiting any classical characteristics of cellular senes-
cence [12].
MSCs within both the perivascular and endosteal
niches possess important roles in facilitating bone repair
processes overall [1, 5]. However, despite bone healing
being a highly organised process, it is recognised that
these mechanisms can be significantly altered and/or im-
paired by the local tissue microenvironment, including
by metabolic, cellular and molecular changes induced
through the uncontrolled glycaemic control and hyper-
glycaemia associated with type 2 diabetes mellitus
(T2DM), initiated as a consequence of insulin resistance
[13, 14]. T2DM and its associated conditions representmajor medical and public health concerns, due to the
ever-increasing prevalence of obesity and the subsequent
incidence of T2DM and related patient morbidities. In-
deed, T2DM is estimated to affect ≅285 million people
worldwide, with projections expecting rises to 438 mil-
lion by 2030 [15]. Consequently, such clinical situations
provide significant economic burdens to healthcare pro-
viders. In this regard, uncontrolled T2DM is recognised
as a mediator of disordered bone metabolism and
homeostasis, leading to it becoming a risk factor for the
development or exacerbation of osteoporosis, fractures,
periodontal disease and orthopaedic/dental implant fail-
ure [16–19].
Due to such correlations, numerous in vitro and in vivo
model studies have examined the underlying mechanisms
by which T2DM influences the metabolic and functional
activities of bone cells. Such studies have identified that
hyperglycaemic conditions affect all stages of bone repair,
with decreased bone formation particularly as a conse-
quence of inhibited osteoblast differentiation and in-
creased apoptosis, induced by oxidative stress and
advanced glycation end products (AGEs) [20–25]; coupled
with altered ECM deposition, turnover and reduced min-
eral formation [26]. Consequently, such outcomes culmin-
ate in osteopenia and delayed bone healing in vivo [27–
29]. Specifically relating to the responses of bone marrow-
derived MSCs (BM-MSCs), high glucose environments
are established to exhibit reduced proliferative capabilities
as a consequence of shortened telomere lengths and early-
onset replicative senescence, which impact on MSC prop-
erties such as viability, multi-potency, colony-forming effi-
ciency (CFEs) and osteogenic differentiation [30–32].
Impaired osteogenesis under hyperglycaemic conditions
occurs at the expense of preferential MSC adipogenic dif-
ferentiation [21, 22, 33]. However, despite the consensus
of studies supporting the deleterious effects of hypergly-
caemia on BM-MSC and osteoblastic responses in bone,
there are conflicting literature reports suggesting limited
effects of high glucose treatment on MSC proliferative
capacity and function [34–36]. Such inconsistencies have
been confounded by inter-study variations in BM-MSC
isolation procedures, the highly variable heterogeneous
nature of BM-MSC populations and the glucose concen-
trations/exposure periods used during in vitro studies. As
most in vitro hyperglycaemia studies have utilised BM-
MSCs derived from the perivascular niche by bone mar-
row aspiration and tissue culture plastic adherence [21,
24, 25, 30–32, 35, 36], there is limited information on the
influences of hyperglycaemic conditions on the other key
MSC populations within the endosteal niche of compact
bone (CB-MSCs) [8–10, 12].
Therefore, in order to provide an insight into the in-
fluence of high glucose levels on MSCs and associated
progenitor cells, heterogeneous CB-MSC populations
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caemic conditions, in terms of their cell proliferative
capacity, cellular senescence characteristics, maintenance
of stem cell characteristics and differentiation potential
towards osteogenic and adipogenic lineages, following
extensive culture in vitro. By further understanding the
effects and susceptibilities of CB-MSCs from the endos-
teal niche to hyperglycaemic conditions, we provide add-
itional clarification of the pathophysiology of diabetic
bone and importantly, highlight the potential impact of
high glucose levels on the metabolism and repair cap-
abilities of CB-MSC populations in situ.
Results
High glucose conditions have no negative impact on CB-
MSC population doublings and expansion
As high glucose conditions have primarily been shown
to reduce proliferative capabilities in BM-MSCs due to
the induction of replicative senescence [30–32, 37], ini-
tial studies assessed the effects of normal (5.5 mM) and
high (25 mM) glucose condition on CB-MSC expansion
over ~ 350 days in culture, expressed as cumulative PDs
(Fig. 1a). CB-MSCs under both normoglycaemic and
hyperglycaemic conditions demonstrated a lag phase
over the initial 70–80 days in culture (10PDs), followed
by rapid exponential growth to >300PDs by ~ 350 days
in culture. However, from ~50PDs (~ 120 days in cul-
ture) onwards, high glucose conditions were determined
to promote more rapid CB-MSC proliferation rates,
compared to normal conditions, which persisted for the
remaining culture duration without any obvious indica-
tions of declining or the onset of cellular senescence.
Extended CB-MSC culture in high and low glucose
conditions alters cell size and morphology
To further examine whether extended CB-MSC expan-
sion over ~ 350 days in culture under normoglycaemic
and hyperglycaemic condition induced changes in cell
size or morphology, CB-MSC morphological characteris-
tics were assessed by cytoskeletal staining with fluores-
cein isothiocyanate (FITC)-phalloidin and fluorescence
microscopy. CB-MSCs under normal (5.5 mM) and high
(25 mM) glucose conditions exhibited considerable alter-
ations in cellular morphologies over the extended cul-
ture expansion period (Fig. 1b). CB-MSCs at PD15
under normoglycaemic and hyperglycaemic conditions
were shown to particularly possess large stellate-shaped
morphologies with the appearance of cytoskeletal stress
fibres; with fewer cells with spindle-shaped, fibroblastic-
like morphologies. CB-MSCs at PD15 in normal and
high glucose conditions were determined to possess the
largest surface areas, which were significantly higher
than those CB-MSCs at other PDs analysed, irrespective
of normal or high glucose treatments (p < 0.001, Fig. 1c).At PD50, CB-MSCs morphologies were generally
smaller, consisting of cells with more spindle-shaped, fi-
broblastic or rounded appearances, compared to PD15
(p < 0.001, Fig. 1b-c); although CB-MSCs under hyper-
glycaemic conditions at PD50 were confirmed to be sig-
nificantly larger than under normoglycaemic conditions
(p < 0.001). Similar trends of declining CB-MSC surface
areas were evident at PD100 and PD200, with the pre-
dominant presence of small stellate and rounded cells
with short processes (Fig. 1b-c). CB-MSCs at PD100 had
the lowest surface areas of all the populations analysed,
particularly under high glucose conditions (p < 0.001).
Similar observations were apparent at PD200, with CB-
MSCs in hyperglycaemic conditions retaining signifi-
cantly decreased surfaces areas, compared to CB-MSCs
under normoglycaemic conditions (p < 0.05).
Expansion under high glucose conditions have limited
impact on the induction of cellular senescence-related
markers in CB-MSCs
A number of studies have reported the increased detection
of replicative senescence markers in BM-MSCs following
culture in high glucose conditions, such as enhanced telo-
mere shortening, positive SA-β-galactosidase staining and el-
evated expression of tumour suppressor (p53) and cyclin-
dependent kinase inhibitor (p21waf1, p16INK4a) senescence
marker genes [30–32, 37]. Consequently, we next asked
whether the levels of these and other relevant telomere
maintenance markers, rat telomerase (rTERT) and telomer-
ase RNA (TR) [38], changed in CB-MSCs, following expan-
sion over ~ 350 days in culture under normoglycaemic and
hyperglycaemic conditions.
During extended culture in normal (5.5 mM) and high
(25 mM) glucose conditions, CB-MSCs demonstrated
limited changes in the induction of cellular senescence,
although these varied depending on the culture expan-
sion periods assessed. Analyses indicated comparable
mean telomere lengths between CB-MSCs at PD15
under normoglycaemic (20.4 kb) and hyperglycaemic
(18.1 kb) conditions (p > 0.05, Fig. 2a, b). However,
whereas mean telomere lengths were significantly longer
in CB-MSCs at PD50 in normal glucose conditions
(28.4 kb, p < 0.01), compared to those at PD15, telomere
lengths remained relatively unchanged between PD15
and PD50 in high glucose conditions (16.7 kb, p > 0.05).
As such, mean telomere lengths were significantly longer
at PD50 under normoglycaemic conditions (p < 0.001).
Significant reductions in telomere lengths were identi-
fied at PD100 under normoglycaemic conditions (14.4
kb), compared to PD50 (p < 0.001); although again, non-
significant reductions in telomere length were detected
between PD50 and PD100 (11.9 kb), under hypergly-
caemic (p > 0.05). As evident at PD50, mean telomere
lengths were significantly longer in CB-MSCs at PD200
Fig. 1 CM-MSC proliferative and morphological characteristics under normoglycaemic and hyperglycaemic conditions. a Cumulative population
doubling (PDs) of CB-MSCs showed rapid expansion from 10PDs (70–80 days) onwards, with high (25 mM) glucose conditions (dotted line),
promoting more rapid CB-MSC proliferation rates from 50PDs (~ 120 days) to >300PDs (~ 350 days), versus normal (5.5 mM) glucose levels (solid
line). b CB-MSC morphologies at PD15, PD50, PD100 and PD200 under normoglycaemic and hyperglycaemic conditions, demonstrated
morphological changes with culture expansion, but few changes due to high (25 mM) glucose conditions. c Quantification of CB-MSC surface
areas at PD15, PD50, PD100 and PD200 under normoglycaemic and hyperglycaemic conditions, confirmed limited influences of high (25 mM)
glucose conditions on CB-MSC morphologies, versus normal (5.5 mM) glucose levels, except at PD100 and PD200. Significance between CB-MSC
populations are shown, ***p < 0.001, **p < 0.01, *p < 0.05. Scale bar = 100 μm
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to those at PD100. However, telomere lengths remained
relatively unchanged in CB-MSCs at PD200 in high glu-
cose conditions (16.3 kb, p > 0.05), compared to PD100.
Consequently, telomere lengths were significantly longer
at PD200 under normoglycaemic conditions (p < 0.001).
Intriguingly, mean telomere lengths showed few correla-
tions with the detection of telomere maintenance markers,
rTERT and TR (Fig. 2c). rTERT was particularly expressed
in CB-MSCs under normoglycaemic conditions at PD15
and PD100, with trace rTERT levels at PD50. In contrast,
rTERT expression gradually declined between PD15 and
PD100 in CB-MSCs under hyperglycaemic conditions.rTERT was undetectable in CB-MSCs at PD200, in both
normal and high glucose conditions. TR expression was
similar in CB-MSCs at PD15, PD50 and PD100 under both
normoglycaemic and hyperglycaemic conditions (Fig. 2c).
However, TR detection declined in CB-MSCs at PD200.
Further analyses indicated that despite significant dif-
ferences in telomere lengths between CB-MSCs in nor-
mal and high glucose conditions at certain stages during
culture expansion, SA-β-galactosidase staining con-
firmed that the majority of cell present in normogly-
caemic and hyperglycaemic conditions were non-
senescent, indicated by < 3% of CM-MSCs per 30 μm2
staining positive (Fig. 2d). This was supported by their
Fig. 2 Characterisation of CB-MSC senescence markers under normoglycaemic and hyperglycaemic conditions. a Telomere length analysis for CB-
MSCs at PD15, PD50, PD100 and PD200, determined by Southern blotting. Right and left hand lanes represent separated DIG-labelled telomere
length standards (kb, in Kit). CTRL represent telomere length positive control (in Kit). b Mean telomere lengths calculated for CB-MSCs at PD15,
PD50, PD100 and PD200, with values ± SE indicated. c Telomere maintenance marker, rTERT and TR, expression at PD15, PD50, PD100 and PD200
under normoglycaemic and hyperglycaemic conditions, by RT-PCR. d Percentage SA-β-galactosidase positive CB-MSCs at PD15, PD50, PD100 and
PD200 under normoglycaemic and hyperglycaemic conditions, demonstrating low (< 3%) positive staining in CB-MSC populations overall.
Significance between CB-MSC populations are shown, ***p < 0.001, **p < 0.01, *p < 0.05
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PD limit for senescent induction at < 0.5PD/week [12, 39]
(Fig. 1a). However, despite such low numbers overall,
higher proportions of senescent cells were present in CB-
MSCs at PD15 and PD50 under hyperglycaemic conditions
(p < 0.05 at PD15), compared to normoglycaemic condi-
tions (Fig. 2d). Furthermore, significantly higher senescent
cell numbers were identified at PD50 under both conditions,
versus CB-MSCs at PD15 in normal glucose concentrations
(p < 0.05 and p < 0.01, respectively). CB-MSCs at bothPD100 and PD200 exhibited the lowest proportions of sen-
escent cells, being significantly lower than CB-MSCs at
PD15 and PD50, under both conditions (p < 0.01).
Analysis of cellular senescence-related genes (p53,
p21waf1 and p16INK4a, Fig. 3a-c respectively), showed that
all CB-MSCs expressed the tumour suppressor gene,
p53 and downstream gene, p21waf1 (regulator of cell
cycle progression at G1 and S phase). p53 demonstrated a
steady increase in gene expression from PD15 until
PD100, which remained expressed at high levels at 200PD.
Fig. 3 Characterisation of CB-MSC senescence marker (p53, p21waf1
and p16INK4a) expression under normoglycaemic and
hyperglycaemic conditions. a Significant differences in p53 gene
expression were shown between PD15 and PD50, PD100 and PD200
under normoglycaemic and hyperglycaemic conditions. However,
only CB-MSCs at PD100 demonstrated significant higher p53
expression in high glucose, compared to normal glucose conditions.
b p21waf1 exhibited very low expression, with no significant
differences in expression between normoglycaemic and
hyperglycaemic conditions. c p16INK4A expression was low across all
PDs, although CB-MSCs at PD15 under both normoglycaemic and
hyperglycaemic conditions demonstrated highest p16INK4A
expression, which declined by PD50 onwards. Significance between
CB-MSC populations are shown, **p < 0.01, *p < 0.05
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sion were shown between PD15 and PD50, PD100 and
PD200 under normoglycaemic and hyperglycaemic condi-
tions (p < 0.05, Fig. 3a). However, only CB-MSCs at
PD100 demonstrated significant higher p53 expression in
high glucose, compared to normal glucose conditions (p <
0.05). In contrast, p21waf1 exhibited very low expression in
all experimental groups, with no significant differences in
expression shown (p > 0.05, Fig. 3b). Expression of another
recognised tumour suppressor gene, p16INK4A, was also
generally low across all PDs, although CB-MSCs at PD15
under both normoglycaemic and hyperglycaemic condi-
tions demonstrated highest p16INK4A expression, which
generally declined by PD50 onwards (p < 0.05 versus
PD50 under normoglycaemic and PD100 under hypergly-
caemic conditions, Fig. 3c).
Extended CB-MSC culture in high and low glucose
conditions has limited impact on stem cell marker
expression, but alters colony forming efficiencies
Many studies have indicated that high glucose conditions
and/or the induction of cellular senescence promotes the
loss of stem cell characteristics in MSC populations, such
as stem cell marker expression and CFEs [12, 30–32, 39].
Therefore, we next investigated whether the expression of
various mesenchymal, haematopoietic, neural crest and
pluripotent stem cell markers changed in CB-MSCs, follow-
ing expansion over ~ 350 days in culture under normogly-
caemic and hyperglycaemic conditions. Similarly, we also
assessed whether the CFEs of CB-MSCs were influenced by
such conditions.
RT-PCR analysis confirmed that CB-MSCs at PD15,
PD50, PD100 and PD200 under normoglycaemic and
hyperglycaemic conditions, positively expressed the mes-
enchymal progenitor cells surface antigens, CD73 (ecto-5-
nucleotidase), CD90 (Thy-1) and CD105 (endoglin) and
were found to be negative for the expression of CD45
(hematopoietic surface antigens) (Fig. 4a). However,
CD105 expression appeared to be lost at PD200 under
hyperglycaemic conditions. CB-MSCs also expressed low
Fig. 4 Characterisation of CB-MSC stem cell properties under normoglycaemic and hyperglycaemic conditions. a CB-MSCs at PD15, PD50, PD100 and
PD200 under normoglycaemic and hyperglycaemic conditions, expressed CD73, CD90 and CD105; and were negative for CD45. CD105 expression
appeared lost at PD200 under hyperglycaemic conditions. CB-MSCs also expressed low levels of CD34 throughout culture expansion, irrespective of
normoglycaemic/hyperglycaemic conditions. CD146, Slug and Snail were expressed throughout expansion under normoglycaemic/hyperglycaemic
conditions. CD106, Nanog and Oct4 expression were undetectable. b Colony forming efficiencies (CFEs) for CB-MSCs at PD15 had significantly lower
efficiencies, compared to PD50, PD100 and PD200, in both normoglycaemic and hyperglycaemic conditions. CFEs at PD50 and PD100 were significantly
higher under hyperglycaemic, compared to normoglycaemic conditions (days 3–5). CFEs were significant decreased at PD200 by hyperglycaemia,
compared to normoglycaemic conditions (days 4–5). Significance between CB-MSC populations are shown, ***p< 0.001, **p< 0.01, *p< 0.05
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of normoglycaemic/hyperglycaemic conditions. Consistent
expression of CD146 and embryonic stem cell markers,
Slug and Snail; were also evident throughout culture ex-
pansion under normoglycaemic/hyperglycaemic condi-
tions. In contrast, expression of CD106 (VCAM-1) and
pluripotent stem cell markers, Nanog and Oct4, were un-
detectable in CB-MSCs.
CFEs indicated that CB-MSCs at PD15 had significantly
lower efficiencies, compared to cells at PD50, PD100 and
PD200, irrespective of normoglycaemic or hyperglycaemic
conditions (all p < 0.001, Fig. 4b). In addition to the signifi-
cant increases in CFEs at PD50 and PD100, these wereshown to be significantly higher under hyperglycaemic con-
ditions on days 3–5 (p < 0.01–0.05), compared to normogly-
caemic conditions. However, significant decreases in CFEs
were identified at PD200 under hyperglycaemic conditions
on days 4–5 (p < 0.001–0.05), compared to normoglycaemic
conditions.
High glucose conditions significantly inhibit CB-MSC
osteogenic differentiation, as does extended culture
expansion under high and low glucose conditions
As high glucose conditions have been shown to nega-
tively impact on the osteogenic differentiation capabil-
ities of BM-MSCs [21, 22, 30–33], we next compared
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ditions on CB-MSC osteogenic capabilities over ~ 350
days in culture.
CB-MSCs cultured in osteogenic medium under normal
(5.5mM) and high (25mM) glucose conditions for 28
days, demonstrated distinct formation of mineralised bone
nodules that stained positive with Alizarin red (Fig. 5a).Fig. 5 Characterisation of CB-MSC osteogenic differentiation under normogly
visualised by Alizarin Red staining, by CB-MSCs cultured for 28 days in osteoin
osteogenic differentiation at PD15, PD100 and PD200, but not at PD50. b Qua
osteoinductive medium, confirming significantly reduced staining at PD15, PD
Assessment of c early (osterix) and d late (OCN) osteogenic marker expression
Q-PCR. CB-MSCs at PD15 under normoglycaemic conditions exhibited signific
PD200. Hyperglycaemic conditions significantly reduced osterix expression at
under hyperglycaemic conditions at day 21. Although OCN expression declin
under normoglycaemic conditions. OCN expression was severely impaired at
conditions exerted no significant effects on OCN expression at PD100 and PD
under normal glucose conditions, at day 28. Significance between CB-MSC poHowever, CB-MSCs in non-osteogenic basal (control)
media demonstrated minimal or no staining. At PD15,
CB-MSCs demonstrated distinct Alizarin red positive
staining in osteogenic medium under normoglycaemic
conditions, but marked decreases in Alizarin red staining
were observed in CB-MSCs at PD50, indicating an overall
impairment in CB-MSC osteogenic capabilities. Althoughcaemic and hyperglycaemic conditions. a Mineral deposition, as
ductive and basal (control) medium. Hyperglycaemia inhibited CB-MSC
ntification of Alizarin red staining by CB-MSCs cultured for 28 days in
100 and PD200 under hyperglycaemic conditions, but not at PD50.
by CB-MSCs under normoglycaemic and hyperglycaemic conditions, by
ant increased osterix expression at day 2, compared to PD50, PD100 and
day 2. CB-MSCs at PD15 exhibited significantly elevated OCN expression
ed by day 28, significantly elevated OCN expression was shown at PD15
PD50 under both normal and high glucose conditions. Hyperglycaemic
200, although significantly increased expression was evident at PD100
pulations are shown, ***p < 0.001, *p < 0.05
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mal glucose conditions at PD100, further reductions in
Alizarin red staining were shown at PD200. When com-
pared to CB-MSCs cultured in osteogenic medium under
hyperglycaemic conditions, consistently less Alizarin red
staining was evident at all PDs examined, versus normo-
glycaemic conditions. Alizarin red staining differences
were confirmed spectrophotometrically (Fig. 5b), with CB-
MSCs at PD15 under normal glucose conditions exhibit-
ing significantly higher stain quantification than at PD50
(p < 0.001). Despite no significant differences in Alizarin
red stain quantification being identified at PD100, com-
pared to CB-MSCs at PD15 (p > 0.05), CB-MSCs at
PD200 demonstrated significantly reduced mineral depos-
ition under normoglycaemic conditions, versus PD15 and
PD100 (p < 0.001 and p < 0.05, respectively). In line with
the Alizarin red histology data, hyperglycaemic conditions
induced significantly reduced Alizarin red stain quantifica-
tion compared to normoglycaemic controls, at PD15,
PD100 and PD200 (all p < 0.05), although no significant
decreases were evident at PD50 (p > 0.05).
Next, we confirmed these results by analysis of osteo-
genic marker (osterix and osteocalcin, OCN) expression
by Q-PCR. Osterix is regarded as an early expressed
gene during osteogenic differentiation and thus, was
quantified at day 2 and day 7. CB-MSCs at PD15 under
normoglycaemic conditions exhibited significant in-
creased osterix expression at day 2, compared to PD50,
PD100 and PD200 (all p < 0.001, Fig. 5c). Conversely,
hyperglycaemic conditions induced significant reduc-
tions in osterix expression at day 2, versus normal glu-
cose conditions (p < 0.001). Although osterix expression
was downregulated by CB-MSCs at PD15 in normogly-
caemic conditions at day 7 (p < 0.001), no significant dif-
ferences in osterix expression between day 2 and day 7
were evident at PD50, PD100 or PD200 (all p > 0.05).
Expression of the late 'osteogenic marker, OCN, was
quantified at day 21 and day 28. At PD15, CB-MSCs ex-
hibited significantly elevated OCN expression under
hyperglycaemic conditions at day 21 (p < 0.001, Fig. 5d).
Although OCN expression declined in high glucose con-
ditions by day 28, significantly elevated OCN expression
was shown for CB-MSCs at PD15 under normogly-
caemic conditions (p < 0.05). In contrast, OCN expres-
sion was severely impaired at PD50 under both normal
and high glucose conditions, compared to PD15 (p <
0.001); with no significant differences in expression in-
duced by hyperglycaemia (p > 0.05). Whilst OCN expres-
sion for CB-MSCs at PD100 and PD200 were similar to
that induced at PD15 at day 21, hyperglycaemic condi-
tions exerted no significant differences on expression,
compared to normoglycaemic conditions. However, sig-
nificant increases in OCN expression by CB-MSCs at
PD100 were evident under normal glucose, compared tohigh glucose conditions, at day 28 (p < 0.05), although
no significant expression differences were identified at
PD200 (p > 0.05).High glucose conditions significantly inhibit CB-MSC
adipogenic differentiation, as does extended culture
expansion under high and low glucose conditions
As impaired BM-MSC osteogenic differentiation under
high glucose conditions has been associated with prefer-
ential adipogenic differentiation [21, 22, 33], we next de-
termined whether similar inductions in CB-MSC
adipogenic capabilities were induced under normogly-
caemic and hyperglycaemic conditions over ~ 350 days
in culture.
CB-MSCs cultured in adipogenic medium under nor-
mal (5.5 mM) and high (25 mM) glucose conditions for
21 days, demonstrated the formation of large lipid drop-
lets that stained positive with LipidTOX™ Green Neutral
Lipid Stain (Fig. 6a). In contrast, CB-MSCs in non-
adipogenic basal (control) media demonstrated minimal
or no staining. At PD15 and PD50, CB-MSCs demon-
strated prominent clusters of positive LipidTOX™ stain-
ing under both normoglycaemic and hyperglycaemic
conditions, whereas CB-MSCs at PD100 and PD200 ex-
hibited fewer lipid vacuoles and a reduced capacity to
differentiate into adipocytes.
Next, we verified these findings results by analysis of
late adipogenic marker (adiponectin and peroxisomal
proliferator-activated receptor-γ, PPARγ) expression by
Q-PCR (Fig. 6b-c, respectively). Although baseline (day
0) analyses demonstrated no significant differences in
adiponectin or PPARγ expression between normal and
high glucose conditions (all p > 0.05), both markers
showed significantly upregulated expression by CB-
MSCs at PD15 and PD50 under normoglycaemic condi-
tions at day 21 (p < 0.001 and p < 0.05, respectively).
Conversely, significant reductions in adiponectin and
PPARγ expression were noted in CB-MSCs at PD100
and PD200, under both normal and high glucose condi-
tions (p < 0.001), resulting in no significant differences in
adiponectin or PPARγ expression between normogly-
caemic and hyperglycaemic conditions at these PDs (all
p > 0.05).Discussion
This in vitro study examined the long-term effects of
hyperglycaemic culture conditions on the properties and
behaviour of heterogeneous CB-MSC populations, de-
rived from the endosteal niche of compact bone [8–10].
The study provides novel information supplementing
previous investigations into MSC populations from the
bone marrow stroma. By focussing on CB-MSCs, we
have evaluated the biological effects of hyperglycaemia
Fig. 6 Characterisation of CB-MSC adipogenic differentiation under normoglycaemic and hyperglycaemic conditions. a Lipid vacuole formation,
as visualised by LipidTOX™ Green Neutral Lipid Stain, by CB-MSCs cultured for 21 days in adipogenic and basal (control) medium. At PD15 and
PD50, CB-MSCs demonstrated prominent LipidTOX™ staining under both normoglycaemic and hyperglycaemic conditions. CB-MSCs at PD100
and PD200 exhibited fewer lipid vacuoles and a reduced capacity to differentiate into adipocytes. Assessment of late adipogenic marker, b
adiponectin and c PPARγ, expression by CB-MSCs under normoglycaemic and hyperglycaemic conditions, by Q-PCR. Although baseline (day 0)
analyses demonstrated no differences in adiponectin or PPARγ expression between normal and high glucose conditions, both showed
significantly increased expression by CB-MSCs at PD15 and PD50 under normoglycaemic conditions at day 21. Significantly reduced adiponectin
and PPARγ expression were identified at PD100 and PD200, under both normal and high glucose conditions. Significance between CB-MSC
populations are shown, ***p < 0.001, *p < 0.05. Scale bar = 100 μm
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prominent roles in bone repair and remodelling [9, 12].
Our data suggests that prolonged expansion under
persistent hyperglycaemic conditions had limited impact
on the proliferative capabilities of heterogeneous CB-
MSC populations as a whole, actually stimulating prolif-
eration between 50-300PDs. Consequently, such findings
are counterintuitive to the consensus of hyperglycaemic
conditions having negative influences on MSC andosteoblast behaviour [20–26], including increased sus-
ceptibility to telomere-dependent, replicative senescence
[30–33]. Nonetheless, in line with high glucose condi-
tions promoting CB-MSC PDs, similar conclusions of
hyperglycaemia having positive or negligible effects on
BM-MSC proliferation rates have also been reported
[34–36].
The lack of negative hyperglycaemic effects on CB-
MSC proliferation were confirmed by cells retaining
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normoglycaemic and hyperglycaemic conditions, the low
numbers of SA-β-galactosidase positive cells and the
limited expression of senescence markers, p53, p21waf1
and p16INK4a. As evident here, similar decreases in cell
size, morphologies and cytoskeletal characteristics have
previously been reported with heterogeneous rat BM-
MSC populations following extensive in vitro culture ex-
pansion [40]. Although CB-MSCs exhibited increased
p53 expression with long-term expansion, only at PD100
were significant increases in p53 expression evident
under hyperglycaemic conditions. MSC replicative sen-
escence is acknowledged as a multi-step process driven
by p53, which promotes growth arrest by inducing
p21waf1 expression, inhibiting G1-S phase progression
[37]. p53 and p21waf1 act as tumour suppressors to regu-
late cell proliferation at rates that provide genomic sta-
bility during MSC division [41]. p53 is also a negative
regulator of pre-osteoblast and pre-adipocyte formation.
Therefore, p53 and p21waf1 expression regulate MSC ex-
pansion in an undifferentiated state. MSC telomere ero-
sion can also initiate p16INK4a checkpoints, suppressing
proliferation and inducing senescence [42]. Conse-
quently, both p53 and p16INK4a are regarded as the prin-
cipal mediators of MSC senescence [43, 44]. However,
despite elevated p53 expression in long-term CB-MSC
culture, the low p21waf1 and p16INK4A expression and
lack of induction by hyperglycaemia, would imply the
absence of any significant promotion of premature CB-
MSC senescence under such conditions.
Maintenance of CB-MSC telomere lengths would be fa-
cilitated by the detection of rTERT and TR during ex-
tended culture expansion [12, 38], which remained
relatively consistent under normoglycaemic and hypergly-
caemic conditions until PD200. Although marker levels
generally discounted the overall presence of enhanced
senescent CB-MSC populations as a whole with increased
glucose exposure, telomere lengths exhibited limited cor-
relations with other senescence markers. Indeed, telomere
length profiles varied considerably during extended cul-
ture expansion under both normoglycaemic and hypergly-
caemic conditions, with CB-MSCs exposed to high
glucose conditions being unable to enhance mean telo-
mere lengths at PD50 and PD200, leading to significantly
decreased telomeres overall. However, significant telomere
length reductions were also identified at PD100 under
normoglycaemic conditions. Such findings are likely to be
associated with the heterogeneous nature of CB-MSCs,
with the loss of minor, more senescent CB-MSC sub-
population(s) with inferior telomere dynamic characteris-
tics at various stages during prolonged expansion [12, 39].
Our previous work has demonstrated that CB-MSCs at
PD15 contained immature/undifferentiated MSCs, in
addition to osteoprogenitor cell and post-mitotic, bonelining osteoblast sub-population(s). However, these ma-
ture osteoblasts were lost by PD50 leading to a more pre-
dominant immature MSC population overall [12].
Therefore, such changes in sub-population composition
may reflect the reductions in telomere length profiles ob-
tained during extended culture expansion, especially
under hyperglycaemic conditions. As rTERT inactivation
by hyperglycaemia is unlikely to contribute to the inability
of CB-MSCs at PD50 and PD200 to maintain telomere
lengths at equivalent levels to normoglycaemic conditions
[45, 46], it appears that particular CB-MSC sub-
population(s) are more susceptible to telomere shortening
and replicative senescence in high glucose conditions, in
line with reports with BM-MSCs [30–32]. However, these
sub-population(s) provide relatively insignificant contribu-
tions to the proliferative capabilities of heterogeneous CB-
MSC populations overall, which are lost during extended
culture expansion.
Although it has been demonstrated that extensive
MSC expansion in vitro may lead to the loss of stem cell
properties and malignant transformation [47, 48], the
proliferative and senescence findings indicated that het-
erogeneous CB-MSC populations under both normogly-
caemic and hyperglycaemic conditions remain non-
transformed during culture expansion. While the prolif-
erative capacities of most cell types are finite, previous
studies involving heterogeneous MSC populations de-
rived from rodent tissues have reported that such cul-
tures retain untransformed states, despite achieving >
100 passages without evidence of cell cycle arrest [40,
49]. Such conclusions are based on the increased expres-
sion of p53 with long-term expansion [37, 41, 50]. Con-
stitutive expression of rTERT and TR throughout
culture expansion also implies that heterogeneous CB-
MSC populations are transformed [51]. However, unlike
humans, rodent cells retain endogenous TERT compe-
tency throughout their lifespans and consequently do
not exhibit classical replicative senescence, leading to
longer telomeres overall [52]. Indeed, positive TERT ex-
pression in human MSCs is associated with the retention
of stem cell properties and inhibition of spontaneous dif-
ferentiation [53].
Further studies examined the ability of CB-MSCs in
normal and high glucose conditions to maintain stem
cell marker expression, form colonies and undergo
osteogenic and adipogenic differentiation. In line with
previous findings, CB-MSCs were positive for MSC
markers, CD73, CD90 and CD105; and negative for
haematopoietic stem cell marker, CD45; although posi-
tive CD34 expression has been previously reported in
CB-MSCs [12]. Neural crest markers, Slug and Snail,
were also expressed at all PDs under normoglycaemic
and hyperglycaemic conditions, as was CD146. Slug and
Snail are implicated in promoting commitment to a
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lished marker of MSC proliferation and multi-potency
[56]. Therefore, expression of these markers may be as-
sociated with continued CB-MSC proliferation during
extended culture, suggesting a level of immaturity and
multi-potency capabilities in some sub-populations.
Consequently, in corroboration of CB-MSCs being re-
sistant to hyperglycaemia inducing premature replicative
senescence, marker expression and stem cell characteris-
tics remained relatively stable throughout the extended
culture expansion period; whereas stem cell marker ex-
pression tends to decline in truly senescent MSC popu-
lations [39, 57].
CB-MSCs at PD15 had significantly lower CFEs, com-
pared to those displayed by CB-MSCs at PD50, PD100
and PD200; irrespective of normoglycaemic or hypergly-
caemic conditions. Such phenomena are suggested to be
related to CB-MSCs at PD15 containing sub-population(s)
of low proliferative, post-mitotic/committed pre-
osteoblasts and osteoblasts from the bone lining cells of
the endosteum [12]. CFEs at PD50 and PD100 were also
significantly higher under hyperglycaemic conditions, al-
though hyperglycaemia reduced CFEs at PD200. There-
fore, at PD50 and PD100, hyperglycaemic conditions were
stimulatory to CFEs, rather than inhibitory in line with the
induction of replicative senescence [30–32]; whereas it is
only at 200PDs where high glucose conditions appear to
be exerting any negative effects on CFEs.
In this study, hyperglycaemia was shown to exert inhibi-
tory effects on the osteogenic differentiation of heteroge-
neous CB-MSC populations at PD15, PD100 and PD200,
evident by decreased mineral deposition and altered
osteogenic marker expression in high glucose conditions.
However, this was not the case at PD50, where in line with
previous findings, marked decreases in mineral staining
and osteogenic marker expression were evident with CB-
MSCs at PD50 under normoglycaemic and hypergly-
caemic conditions [12]. The particularly high osteogenic
capacity of CB-MSCs at PD15 under normoglycaemic
conditions are a likely consequence of the presence of
more mature/committed osteoprogenitor and pre-
osteoblastic stromal cells, proposed to be present within
the endosteal niche [9, 10, 12]. Impaired osteogenic re-
sponses at PD50 suggest a change in the overall compos-
ition of the heterogeneous CB-MSC population between
PD15 and PD50, to one predominantly consisting of more
immature, multi-potent MSC populations [12]. As such,
the delayed induction of osterix expression, coupled with
the early onset of OCN expression, suggests perturbations
to normal ECM formation and mineralisation within high
glucose environments, especially at PD15 [23, 58, 59]. In
contrast, fewer differences in mineral content and osterix/
OCN expression were evident between normoglycaemic
and hyperglycaemic conditions at PD50, PD100 or PD200,possibly due to extended culture conditions impeding nor-
mal CB-MSC osteogenic capabilities at higher PDs influ-
encing ECM deposition, even under normal glucose
conditions. Similar findings of high glucose conditions
inhibiting osteogenic differentiation, bone ECM depos-
ition and overall mineralisation have been reported previ-
ously, with lesser quality bone formed [20–32].
In terms of adipogenesis, CB-MSCs at PD15 and PD50
demonstrated similar LipidTOX™ staining indicative of
adipogenic capabilities irrespective of normoglycaemic or
hyperglycaemic conditions, although expression of both
adiponectin and PPARγ were significantly impaired in
high glucose conditions. Such findings are partly counter-
intuitive to previous reports that CB-MSCs demonstrate
enhanced adipogenic induction at PD50, compared to
PD15 [12]. Nonetheless, the increased osteogenic commit-
ment of CB-MSC at PD15 did not negate adipogenic dif-
ferentiation, implying the additional presence of immature
cell sub-population(s) with adipogenic capabilities. Despite
abrogated osteogenic responses at PD50, CB-MSCs exhib-
ited improved adipogenic differentiation, possibly due to
the absence of committed osteoprogenitor cells, enabling
immature cell differentiation into adipocytes. In contrast,
CB-MSCs at PD100 and PD200 exhibited reduced adipo-
genesis overall. Consequently, no differences in adipogenic
marker expression were evident between CB-MSCs in
normal and high glucose conditions at PD100 and PD200,
indicating the disruption of CB-MSC adipogenic capabil-
ities at higher PDs. It is established that hyperglycaemia
can alter gene expression and drive MSC differentiation
towards the adipogenic lineage [21, 22, 33]. Therefore,
CB-MSC adipogenic responses at all PDs analysed are
mostly contradictory to this phenomenon, given the com-
parable or impaired LipidTOX™ staining and adipogenic
marker expression identified herein under hyperglycaemic
conditions; although failed adipogenic differentiation as
evident at PD100 and PD200 has previously been reported
following extended in vitro culture expansion [60]. As in-
creases in adipogenic capabilities are often associated with
impaired osteogenesis, the collective conclusions on the
abilities of hyperglycaemia to influence CB-MSC osteo-
genic/adipogenic differentiation are that high glucose con-
ditions can inhibit osteogenic differentiation, although this
does not necessarily increase adipogenesis.
The reasons behind increased CB-MSCs susceptibil-
ities to disrupted osteogenic (at PD50 and PD200) and
adipogenic (at PD100 and PD200) differentiation, remain
to be elucidated. However, factors such as additional al-
terations to osteogenic/adipogenic gene expression other
than those evaluated here, CB-MSC populations posses-
sing lower mean telomere lengths (such as PD100); or
CB-MSCs at PD50 being less lineage restricted due to
the loss of more mature/committed sub-population(s)
present at earlier PDs, are all plausible explanations for
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T2DM is commonly associated with insulin resistance,
hyperinsulinemia and metabolic disturbances leading to
altered cell signalling and genotypic/phenotypic re-
sponses [13, 14]. Although insulin stimulates osteogenic
proliferation, differentiation and bone formation via in-
sulin growth factor (IGF) receptor binding and down-
stream signalling pathway activation [61], such
responses differ in T2DM due to insulin resistance and
absence of IGF receptor stimulation. Indeed, T2DM pa-
tients treated with insulin have an increased risk of frac-
ture development, related to compromised bone
strength [62]. Consequently, the impact of hypergly-
caemic conditions on the levels and signalling mecha-
nisms of insulin and other key bone repair-related
mediators in CB-MSCs, such as IGFs, transforming
growth factor-β1 (TGF-β1) and bone morphogenic pro-
teins (BMPs), warrant further investigation; especially in
terms of whether disruptions to such signalling pathways
contribute to impaired osteogenic/adipogenic differenti-
ation capabilities in CB-MSCs.
It has further been proposed that high glucose effects
on MSC populations differ depending on their levels of
stemness and whether TA cells or more lineage re-
stricted MSC populations are present [34]. Asymmetric
cell division by MSCs produces highly proliferative, im-
mature TA cells, capable of forming colonies and multi-
potency; alongside more quiescent, mature TA cell pop-
ulations with lower colony forming efficiencies, more re-
stricted lineage potentials [11, 12, 39]. As such, despite
proliferative responses being largely unaffected by ex-
tended culture expansion, CB-MSCs at PD15 represent a
pool of more committed and lineage restricted cell pop-
ulations, which are subsequently lost during expansion
at PD50, PD100 and PD200 under normoglycaemic and
hyperglycaemic conditions, leading to a predominance of
more multi-potent immature TA cells with delayed or
impaired osteogenic and adipogenic differentiation cap-
abilities [9, 10, 12]. Consequently, as lineage restricted
MSCs are proposed to be the first responders during
mineralised tissue repair, prolonged expansion may in-
fluence the overall compositions of CB-MSC populations
with key roles in mediating bone healing.
Conclusions
Although MSCs have key roles in bone repair, hypergly-
caemia associated with T2DM can impair healing. This
study has demonstrated that unlike previous reports on
the increased susceptibility of other BM-MSCs to hyper-
glycaemic conditions, heterogeneous CB-MSC popula-
tions derived from the endosteal niche of compact bone
are largely unaffected by prolonged exposure to high
glucose conditions, in terms of their proliferative re-
sponses and the retention of stem cell characteristics.However, osteogenic and adipogenic differentiation re-
sponses were significantly impaired under high glucose
conditions. Despite the heterogeneous CB-MSC popula-
tions being collectively resistant to detrimental hypergly-
caemic effects, minor more senescent CB-MSC sub-
population(s) showed increased susceptibility to hyper-
glycaemia. Although the loss of these sub-population(s)
during extended culture expansion exerted relatively lit-
tle impact on the proliferative or stem cell characteristics
of CB-MSCs overall, their absence negatively impacted
on osteogenic and adipogenic differentiation capabilities.
Whereas previous reports have mostly focused on BM-
MSCs, this study provides a unique insight into the in-
fluence of high glucose levels on heterogeneous CB-
MSC populations. The data presented provides an im-
portant initial characterisation of these effects, leading to
a better understanding of the potential impact of high
glucose levels on the metabolism and repair capabilities
of CB-MSC populations in situ and the pathophysiology
of diabetic bone; which has significant impacts on the
clinical management of orthopaedic and dental condi-
tions, due to the ever-increasing incidence of T2DM
worldwide.
Methods
Isolation of CB-MSCs and culture expansion under high
and low glucose conditions
CB-MSCs were isolated from 28-day old male Wistar rat
femur and humerus bones, as previously described [12].
Wistar rats (110–130 g, n = 4) were obtained from the
colony maintained by Charles River (Margate, UK). Ani-
mals were housed in individual cages under standard
light/dark cycle, with access to food (standard chow)
and water ad libitum. This study was performed in ac-
cordance with the Basel Declaration guidelines on the
care and use of laboratory animals. Rats were maintained
with standard treatment and care, in accordance with
the UK Animals (Scientific Procedures) Act 1986. Rats
were sacrificed by CO2 asphyxiation, in accordance with
Code of Practice for the Humane Killing of Animals,
under Schedule 1 of the Animals (Scientific Procedures)
Act, 1986. Animal studies are reported in compliance
with the ARRIVE guidelines (https://www.nc3rs.org.uk/
arrive-guidelines, [63]).
CB-MSCs were isolated from the long bones, as previ-
ously described [12]. CB-MSCs were subsequently ex-
panded at 37 °C/5% CO2 in normal glucose (5.5 mM) or
high glucose (25 mM) complete culture medium (CCM),
consisting of αMEM with ribonucleosides and deoxyri-
bonuclosides, supplemented with 20% heat-inactivated
foetal bovine serum (FBS, ThermoFisher Scientific, Pais-
ley, UK), 1% antibiotics-antimycotics and 100 μML-
ascorbic acid 2-phosphate (both Sigma-Aldrich, Poole,
UK); for ~ 350 days in culture [12].
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Upon reaching 70–80% confluence, CB-MSCs in normal
(5.5 mM) and high (25 mM) glucose were treated with
StemPro® Accutase® (ThermoFisher Scientific) and PD
rates calculated from cell counts throughout the ~ 350
days in culture, as previously described [12, 39]. Cumu-
lative PDs were subsequently plotted against time in cul-
ture, with the onset of cellular senescence confirmed
when CB-MSCs underwent < 0.5PDs/week [12, 39].
Cell morphology analysis
CB-MSC morphologies at PD15, PD50, PD100 and
PD200 under normal (5.5 mM) and high (25 mM) glu-
cose conditions, were examined using FITC-phalloidin
staining and fluorescence microscopy (Olympus Provis
AX70 Microscope, Olympus UK Ltd., Southend-on-Sea,
UK), as previously described [12]. CB-MSC surface areas
were quantified by ImageJ Software (NIH Software, Ver-
sion 1.49).
Telomere length determination
Following DNA purification, CB-MSC telomere length
assessments at PD15, PD50, PD100 and PD200 in nor-
mal (5.5 mM) and high (25 mM) glucose, were per-
formed using the TeloTAGGG Telomere Restriction
Fragment Length (TRF) Assay Kit (Roche, Welwyn Gar-
den City, UK). Mean telomere lengths were subsequently
calculated from Southern blot images using ImageJ®
Software, as previously described [12, 39].
Senescence associated-β-galactosidase staining
CB-MSCs senescence at PD15, PD50, PD100 and PD200
under normal (5.5 mM) and high (25 mM) glucose con-
ditions, was assessed by the presence of senescence asso-
ciated (SA)-β-galactosidase staining, using a Senescence
Cells Histochemical Staining Kit (Sigma-Aldrich), as pre-
viously described [12, 39].
Quantitative real-time PCR
For the determination of cellular senescence marker
(p53, p21waf1 and p16INK4a) expression by CB-MSCs at
PD15, PD50, PD100 and PD200 in normal (5.5 mM) and
high (25 mM) glucose using quantitative real-time poly-
merase chain reaction (Q-PCR), total RNA extraction
and cDNA generation were performed, as previously de-
scribed [12, 39]. For each Q-PCR reaction, 2 μL of 3 μM
primers (forward and reverse sequences detailed in
Table 1; all Primer Design Ltd., Southampton, UK), were
mixed with 10 μL of 2x Precision FAST Q-PCR Master
Mix (Primer Design); and 1 μL nuclease-free water. 5 μL
cDNA (1 μg isolated cDNA, diluted 1,10 in nuclease-free
water), was applied in triplicate into 96-well Q-PCR
plates (Primer Design), followed by 15 μL of pre-
prepared Master Mix. Q-PCR reactions were run on aQuantStudio™ 6 Flex Real-Time PCR System Machine
(ThermoFisher Scientific), using QuantStudio™ Real-
Time PCR Software (v1.0). Reaction conditions had an
initial denaturing step of 95 °C (20 s), followed by 40 cy-
cles at 95 °C (1 min), 1 annealing cycle of 62 C (20 s), de-
naturation at 95 °C (15 s), dissociation at 60 °C (1 min);
and denaturation at 95 °C (15 s). GAPDH served as an
internal control for data normalisation. Gene expression
quantification was calculated using the ΔCt method,
through gene expression as a percentage of the GAPDH
housekeeping gene [12].
Reverse transcription PCR
Reverse transcription PCR was employed for the deter-
mination of senescence (rTERT and TR) and stem cell
(CD73, CD90, CD105, CD34, CD45, CD106, CD146,
Nanog, Oct4, Slug and Snail) marker expression; by CB-
MSCs at PD15, PD50, PD100 and PD200 under normal
(5.5 mM) and high (25 mM) glucose conditions. Total
RNA extraction, cDNA generation and PCR reactions
were performed as previously described [12, 39], using
primer sequences described in Table 1, with β-actin
serving as the reference housekeeping gene. PCR prod-
ucts and 100 bp DNA ladders (Promega, Southampton,
UK) were separated on 2% agarose gels in 1x Tris-
acetate-EDTA buffer. Images were captured under UV
light and analysed as previously described [12, 39].
Colony forming efficiencies
CB-MSCs colony forming efficiencies at PD15, PD50,
PD100 and PD200 in normal (5.5 mM) and high (25
mM) glucose were determined as previously described,
with colonies defined as containing > 32 cells [12, 64].
Assessment of osteogenic differentiation
The osteogenic differentiation capabilities of CB-MSCs at
PD15, PD50, PD100 and PD200 under normal (5.5mM)
and high (25mM) glucose conditions, were determined
following CB-MSC culture in normal (5.5mM) and high
(25mM) glucose, osteogenic medium (consisting of
αMEM with ribonucleosides and deoxyribonuclosides,
supplemented with 10% FBS, 1% antibiotics-antimycotics,
100 μML-ascorbic acid 2-phosphate, 10 nM dexametha-
sone and 100mM β-glycerophosphate; all Sigma-Aldrich)
[12, 39]. Negative controls were also established, with CB-
MSCs remaining in non-osteogenic basal medium in nor-
mal (5.5mM) and high (25mM) glucose conditions. Cells
were maintained at 37 °C/5% CO2 for 28 days, with culture
medium changed every 2 days.
Total RNA was extracted and mRNA expression of
osteogenic markers, osterix and OCN (both Primer De-
sign, Table 1); examined on day 2 and day 7 (osterix)
and day 21 and day 28 (OCN) by Q-PCR, as above. At
day 28, cells were also assessed for mineral calcium
Table 1 Primers sequences for RT-PCR and Q-PCR analysis
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39]. The extent of mineral formation was also quanti-
fied, as previously described [65]. Absorbance values
were measured using a SPECTROstar Omega Micro-
plate Spectrophotometer (BMG Labtech, Aylesbury,
UK), at 405 nm.Assessment of adipogenic differentiation
The adipogenic differentiation capabilities of CB-MSCs
at PD15, PD50, PD100 and under normal (5.5 mM) and
high (25 mM) glucose conditions, were determined fol-
lowing CB-MSC culture in normal (5.5 mM) and high
(25 mM) glucose, adipogenic induction medium (AIM,
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nuclosides, supplemented with 10% FBS, 1% antibiotics-
antimycotics, 100 μML-ascorbic acid 2-phosphate, 1 μM
dexamethasone, 100 μM 3-isobutyl-1-methyxanthine and
100 μM indomethacin; all Sigma-Aldrich) [12]. Negative
controls were also established, with CB-MSCs remaining in
non-adipogenic basal medium in normal (5.5mM) and
high (25mM) glucose conditions. Cells were maintained at
37 °C/5% CO2 for 6 days, with culture medium changed
every 2 days. AIM was subsequently replaced by normal
(5.5mM) and high (25mM) glucose, adipogenic mainten-
ance medium (AMM, consisting of αMEM with ribonucle-
osides and deoxyribonuclosides, supplemented with 10%
FBS, 1% antibiotics-antimycotics, 100 μML-ascorbic acid 2-
phosphate and 10 μg/mL insulin; all Sigma-Aldrich) [12].
Cells were maintained at 37 °C/5% CO2 for 2 days and re-
cultured in AIM with normal (5.5mM) or high (25mM)
glucose, until day 15, followed by repeated culture in AMM
until day 17 and culture in AIM until day 21.
Total RNA was extracted and mRNA expression of
adipogenic markers, adiponectin and PPARγ (both Pri-
mer Design, Table 1); examined on day 0 and 21 by Q-
PCR, as described above. At day 21, cells were also
assessed for intracellular lipid-rich vacuole accumula-
tion. Cells were transferred to glass chamber slides (BD
Biosciences, Oxford, UK), fixed with 4% paraformalde-
hyde solution (Santa Cruz, Dallas, USA) and stained
with HCS LipidTOX™ Green Neutral Lipid Stain (1:200
in phosphate buffered saline, PBS; ThermoFisher Scien-
tific), according to manufacturer’s instructions. Cells
were washed in PBS (× 3), slide chambers removed and
stained with DAPI Vectashield Hard-Set Mounting
Medium (Vector Laboratories, Peterborough, UK). Cov-
erslips were added and images captured by fluorescence
microscopy, as above.
Statistical analysis
Data were expressed as mean ± standard error of mean
(SEM). Data were statistically compared using Analysis
of Variance (ANOVA), with post-hoc Tukey test. Statis-
tical significance was considered at p < 0.05.
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